This grant supports innovative, hypothesis-driven research projects addressing critical unmet needs in monosomy 7 and other high-risk cytogenetic AML subtypes. Funded research may be basic, translational, clinical, or population sciences focused on disease mechanisms, therapeutic vulnerabilities, biomarkers, treatment strategies, survivorship, and disparities. The goal is to improve diagnosis, risk stratification, therapeutic targeting, response prediction, and long-term outcomes for patients with high-risk AML.
Applicants must hold a doctoral degree and be independent investigators at academic, medical, or research institutions worldwide. They cannot be doctoral candidates, federal government employees, or concurrently hold another AACR grant. AACR Active Membership in good standing is required.
